Woodley Trial Solutions

04/09/2026

"Hope is the biggest thing, the chance to be free from the (dialysis) machine and live your life."

That's Tim Andrews. He's 66. He received a kidney transplanted from a pig, and had it functioning in his body for a record 271 days.

In the US, around 100,000 people are waiting for a kidney. Only 25,000 transplants happen each year. Tim was told it could take seven years to reach the top of the waiting list. The average life expectancy on dialysis is five years. That gap is what xenotransplantation research is trying to close.

Researchers used Yucatan miniature pigs with 69 genomic modifications to make their organs less likely to be rejected. Tim's transplanted kidney worked immediately. It gave him 271 days free from dialysis before it was eventually removed. A human donor kidney followed and is working well.

The doctors who published the findings in the Lancet describe it as illustrating both the promise and the remaining challenges. It isn't finished science. But it's moving, and it matters.

At Woodley Trial Solutions, moments like this remind us why we do what we do. Every clinical trial we support, every piece of equipment that reaches a site, every patient who gets to participate in research - it's all part of helping to find treatments and cures that give people exactly what Tim described.

Hope.

Read the full article here 👇
🔗 https://www.bbc.co.uk/news/articles/c305qn2jeggo

A man has lived for a record nine months with a transplanted pig kidney while waiting for a human transplant.

04/09/2026

Up to 80% of clinical trials miss their enrolment timelines.

Most of those delays don't start with the science. They start with a central lab result that takes 48 hours, a patient who doesn't come back for a follow-up visit, a screening window that closes before the eligibility decision is made.

Point of Care Testing moves that decision to the screening visit itself. Result in minutes. Eligibility confirmed. Enrolment decision made before the patient leaves the building.

According to the Tufts Center for the Study of Drug Development, a single day's delay in a Phase II or III clinical trial costs around $40,000. POCT at screening doesn't just improve the patient experience. It directly protects the study timeline.

Woodley Trial Solutions supplies POCT devices across cardiovascular, metabolic, haematological, renal and hepatic panels. Our POCT team works with study teams at protocol stage to recommend the right device for specific endpoints.

For a free consultation on where POCT can fit into your study, get in touch 👇
🔗 woodleytrialsolutions.com/solutions/point-of-care-testing-poct

04/09/2026

If you live with migraines, you'll know they're not just headaches.

New research from Norway is starting to back that up biologically. Researchers used AI and genetic data from more than 43,000 people to identify migraine patients...without looking at headache symptoms at all. The AI could still identify them accurately, suggesting migraine leaves a much broader biological footprint than the pain alone.

The study then identified four distinct subgroups within migraine patients: one predominantly male, one characterised by neck pain, one linked to musculoskeletal pain alongside anxiety and depression, and one resembling classic migraine with aura.

That matters because it raises the possibility that migraine isn't one condition. It's a spectrum of different biological disorders which could eventually explain why a treatment that transforms life for one patient does almost nothing for another.

AI-assisted research like this is what clinical trials are increasingly making possible. The science is catching up with what patients have known for years.

Read the full article here 👇
🔗 https://www.euronews.com/health/2026/09/04/ai-is-starting-to-see-migraine-as-more-than-just-a-headache

Researchers used artificial intelligence and genetic data from more than 43,000 people to identify biological patterns that could reshape how one of the world’s most common neurological disorders is diagnosed and treated.

04/09/2026

Today is World Leukaemia Day. And as a company working at the heart of clinical research, it feels important to use our platform to help raise awareness.

Leukaemia is a cancer of the blood and bone marrow. It affects people of all ages and the numbers behind it are significant:
🔴 Over 300,000 deaths are caused by leukaemia every year
🔴 It is the 13th most common cancer in the world, and the 10th most common in men globally
🔴 In people aged 0–29, leukaemia accounts for almost one in five of all cancer diagnoses

We are fortunate to work in an industry that is actively pushing forward on treatments and potential cures through the clinical trials and research programmes that are giving patients more options, better outcomes and more time.

Today we want to do our small part in raising awareness.

If you found this useful, please like or repost to help us shine a light. ❤️

Find out more about leukaemia and its symptoms here 👇
🔗 https://www.worldleukemiaday.org/

See less

03/09/2026

Most clinical trials assume a central laboratory is within reach. This one couldn't.

Woodley Trial Solutions worked with Fortrea on a Phase II malaria study investigating a novel therapy across 17 sites in 11 countries in sub-Saharan Africa and India. Central labs weren't an option.

The solution was a bespoke decentralised POCT setup built specifically for the trial. Devices from different manufacturers integrated into a single seamless protocol. Real-time data transmission to the sponsor. Custom training programmes delivered online, with French language translators, to local site teams. Temperature-controlled logistics and IoR services managing supplies across 11 sets of customs regulations. Live technical support throughout.

According to the WHO, there were an estimated 263 million malaria cases globally in 2023, with 597,000 deaths. Africa accounts for 94% of that burden. The patients in this study live in the regions that need this research most. And the decentralised lab model makes it possible to reach them.

Find out how it came together in our case study here👇
🔗 https://woodleytrialsolutions.com/malaria

03/09/2026

The device a patient holds in a clinical trial tells them something about whether the study thought about them.

If it's unfamiliar, hard to navigate or in a language they don't speak, the friction shows up fast. Compliance dips. Data quality follows.

Woodley Trial Solutions supplies mobile devices, tablets and wearables configured and study-ready before they reach the site. They are available in the patient's language, robust for daily real-world use, and connected via global SIM so data transfers securely to your CRO without delay.

Patients who find their device easy to use are more likely to stay in the study. Studies with clean, continuous data are more likely to stay on schedule.

The device matters. We make sure it's the right one. 📲

Find out more and get in touch 👇
🔗 https://woodleytrialsolutions.com/DHT

02/09/2026

This is the kind of clinical research news worth stopping for.

An at-home urine test trialled by the NHS can detect more than 92% of bladder cancer cases. A negative result carries a greater than 99% probability of being clear. No hospital visit. No invasive procedure for an initial screen.

The test was developed at the University of Birmingham, funded by Cancer Research UK, and validated across nearly 1,000 patients at seven hospitals.

Early diagnosis changes outcomes. And breakthroughs like this don't reach patients without clinical trials and the people who take part in them.

Read more here: https://www.bbc.co.uk/news/articles/crr40g71vylo



The NHS has been trialling the test and says the results so far are truly promising.

01/09/2026

September is Blood Cancer Awareness Month. For those of us working in clinical trials, it's a month that sits close.

Blood cancer isn't one disease. It covers a broad group of conditions - leukaemia, lymphoma, myeloma and others - affecting the blood, bone marrow and lymphatic system. Despite being the third most common cancer type globally, it remains one of the least understood. In the UK, more than half of adults cannot name a single symptom.

The scale of it:
🔴 1.3 million+ people diagnosed with blood cancer globally each year
🔴 Every three minutes, someone in the world receives that diagnosis
🔴 Third most common cancer type across all age groups worldwide

The progress is real too. Two-thirds of blood cancer patients over 80 now survive five years or more - a number that has transformed over recent decades. That didn't happen by chance. It happened because of clinical research. Because of CAR-T therapy moving from concept to treatment. Because of researchers, clinicians, site teams and patients who gave their time to trials that changed what's possible.

Clinical trials are at the heart of that progress.

This month we've published an awareness article covering blood cancer symptoms, why early recognition matters, and some of the advances being made through clinical research. We hope it's useful - whether you work in haematology research or simply want to know more.

Read it here 👇
https://woodleytrialsolutions.com/news/blood-cancer-awareness-month-the-signs-worth-knowing-and-the-research-changing-what-a-diagnosis-means

If blood cancer has touched your life or someone you care about, our thoughts are with you this September. 🎗️

27/08/2026

Metabolic data is only as good as the chain that carries it - from patient to sensor to CRO, without gaps.

Dexcom G7 is the CGM device we get asked about most for metabolic and cardiometabolic studies. Real-time continuous glucose monitoring, no fingerstick calibration required, 10-day sensor life. Data transfers securely to CROs through third party provider, whether in-clinic or remote, across 8,500+ clinics worldwide, in 20+ languages.

Woodley Trial Solutions has been supporting metabolic studies with CGM technology for years. We supply the Dexcom G7 globally, manage the logistics, and work with study teams from protocol stage to make sure the device fits the study design.

Running a metabolic study? Challenge us with your requirements 👇
🔗 https://woodleytrialsolutions.com/solutions/metabolic-monitoring

26/08/2026

It starts with something small. 📦

A missing item. A form in the wrong language. A device the site wasn't trained on.

Then a patient waits. A visit gets rescheduled. A data point is missed. A protocol deviation is filed.

Kitting done properly stops the first domino falling.

Woodley Trial Solutions Site-Ready Patient Kits are built to your protocol, pre-packed, quality-checked and globally delivered — so the kit that arrives at your site is ready to use, not ready to cause problems.

Find out more 👇
🔗 woodleytrialsolutions.com/solutions/site-ready-patient-kits